157 related articles for article (PubMed ID: 37758535)
1. Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis.
Stephenson KG; Lingle AJ; Baumberger KA; Dellon EP; Esther CR; Meier EM; Oermann CM; Shenoy VK; Smith NR; Wimmer NS; Duehlmeyer SR; Kam CW; McKinzie CJ; Poisson MO; Elson EC
J Cyst Fibros; 2023 Nov; 22(6):996-1001. PubMed ID: 37758535
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review.
Ramsey ML; Li SS; Lara LF; Gokun Y; Akshintala VS; Conwell DL; Heintz J; Kirkby SE; McCoy KS; Papachristou GI; Patel A; Singh VK; Hart PA
J Cyst Fibros; 2023 Mar; 22(2):193-200. PubMed ID: 36008229
[TBL] [Abstract][Full Text] [Related]
3. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
De Boeck K; Weren M; Proesmans M; Kerem E
Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
[TBL] [Abstract][Full Text] [Related]
4. Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy.
Yuzyuk T; McDonald CM; Zuromski LM; De Biase I; Johnson L; Williams N; Meihls S; Asfour F
J Cyst Fibros; 2023 Nov; 22(6):1027-1035. PubMed ID: 37453889
[TBL] [Abstract][Full Text] [Related]
5. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
6. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis.
Ramsey ML; Gokun Y; Sobotka LA; Wellner MR; Porter K; Kirkby SE; Li SS; Papachristou GI; Krishna SG; Stanich PP; Hart PA; Conwell DL; Lara LF
Am J Gastroenterol; 2021 Dec; 116(12):2446-2454. PubMed ID: 34665155
[TBL] [Abstract][Full Text] [Related]
7. CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis.
Gould MJ; Smith H; Rayment JH; Machida H; Gonska T; Galante GJ
J Cyst Fibros; 2022 Jul; 21(4):600-602. PubMed ID: 34732308
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
[TBL] [Abstract][Full Text] [Related]
9. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
10. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.
Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C
Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799
[TBL] [Abstract][Full Text] [Related]
11. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
12. Faecal elastase-1 concentration in cystic fibrosis patients with CFTR I1234V mutation.
Abdel Rahman H; Abdul Wahab A; Abdel Rahman MO; Mostafa OA
Acta Paediatr; 2006 Sep; 95(9):1066-9. PubMed ID: 16938751
[TBL] [Abstract][Full Text] [Related]
13. CFTR Modulators: Current Status and Evolving Knowledge.
Regard L; Martin C; Da Silva J; Burgel PR
Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
[TBL] [Abstract][Full Text] [Related]
14. Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with
Tabori H; Schneider J; Lüth S; Zagoya C; Barucha A; Lehmann T; Kauf E; Barth A; Mainz JG
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293293
[TBL] [Abstract][Full Text] [Related]
15. Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population.
Albright JC; Houck AP; Pettit RS
Pediatr Pulmonol; 2020 Oct; 55(10):2662-2666. PubMed ID: 32568427
[TBL] [Abstract][Full Text] [Related]
16. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.
Munce D; Lim M; Akong K
Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556
[TBL] [Abstract][Full Text] [Related]
17. Serum zinc concentration in cystic fibrosis patients with CFTR I1234V mutation associated with pancreatic sufficiency.
AbdulWahab A; Abushahin A; Allangawi M; Chandra P; Abdel Rahman MO; Soliman A
Clin Respir J; 2017 May; 11(3):305-310. PubMed ID: 26096753
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of fecal pancreatic elastase-1 as a measure of pancreatic exocrine function in children with cystic fibrosis.
Cade A; Walters MP; McGinley N; Firth J; Brownlee KG; Conway SP; Littlewood JM
Pediatr Pulmonol; 2000 Mar; 29(3):172-6. PubMed ID: 10686036
[TBL] [Abstract][Full Text] [Related]
19. A foetus with cystic fibrosis - To treat or not to treat?
Padmakumar N; Khan HS
Respir Med Res; 2023 Jun; 83():101006. PubMed ID: 37037055
[TBL] [Abstract][Full Text] [Related]
20. A grumbling concern: an international survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.
Calthorpe RJ; Goodchild N; Gleetus V; Premakumar V; Hayee B; Elliott Z; Evans B; Rowbotham NJ; Carr SB; Barr H; Horsley A; Peckham D; Smyth AR
NIHR Open Res; 2023; 3():18. PubMed ID: 37881465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
